{"id":"testosterone-md-lotion","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Acne"},{"rate":"1-5%","effect":"Increased red blood cell count"}]},"_chembl":{"chemblId":"CHEMBL1200335","moleculeType":"Small molecule","molecularWeight":"400.60"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This topical lotion is designed to bypass the gastrointestinal tract and liver, allowing for direct absorption into the bloodstream via the skin, thereby restoring physiological levels of testosterone in hypogonadal men.","oneSentence":"Testosterone MD-Lotion delivers testosterone through the skin to replace deficient levels in the body.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:09.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypogonadism in adult males"}]},"trialDetails":[{"nctId":"NCT00702650","phase":"PHASE3","title":"A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Hypogonadism","enrollment":155},{"nctId":"NCT00857961","phase":"PHASE2","title":"A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2007-10","conditions":"Hypogonadism","enrollment":21},{"nctId":"NCT00857454","phase":"PHASE3","title":"A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-10","conditions":"Hypogonadism","enrollment":71},{"nctId":"NCT01172366","phase":"","title":"A Study to Evaluate the Potential for Interpersonal Transfer of Testosterone Following Single Dose Application","status":"COMPLETED","sponsor":"Acrux DDS Pty Ltd","startDate":"2010-08","conditions":"Hypogonadism","enrollment":20},{"nctId":"NCT00996151","phase":"PHASE1","title":"Testosterone MD-Lotion Residual Washing Study","status":"COMPLETED","sponsor":"Acrux DDS Pty Ltd","startDate":"2009-12","conditions":"Hypergonadism","enrollment":10},{"nctId":"NCT00857168","phase":"PHASE1","title":"To Determine the Effects of Deodorant, Antiperspirant and Washing on the Pharmacokinetics of 2% Testosterone MD Lotion","status":"COMPLETED","sponsor":"Acrux DDS Pty Ltd","startDate":"2009-01","conditions":"Hypogonadism","enrollment":36},{"nctId":"NCT00372008","phase":"PHASE2","title":"Pharmacokinetics of Testosterone Lotion in the Treatment of Hypogonadal Males","status":"COMPLETED","sponsor":"Acrux DDS Pty Ltd","startDate":"2006-10","conditions":"Hypogonadism","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY900011","Axiron"],"phase":"phase_3","status":"active","brandName":"Testosterone MD-Lotion","genericName":"Testosterone MD-Lotion","companyName":"Acrux DDS Pty Ltd","companyId":"acrux-dds-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Testosterone MD-Lotion delivers testosterone through the skin to replace deficient levels in the body. Used for Hypogonadism in adult males.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}